跳至主要内容
临床试验/NCT02420951
NCT02420951已完成不适用

Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery

Brigham and Women's Hospital0 个研究点目标入组 50 人开始时间: 2015年10月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
50
主要终点
Pain Assessed Using the VAS 0-10 Pain Scale

研究概览

简要总结

The purpose of this study is to determine if an additional injection of local anesthetic immediately prior to removal of the local anesthetic infiltration catheter on postoperative day one is effective in increasing pain reduction, patient satisfaction or outcome measures following total knee replacement (TKR). It is hypothesized that an additional injection of 30ml of .5% bupivacaine solution immediately before infiltration catheter removal will provide pain reduction, patient satisfaction and outcome measures equal or superior to catheter removal with no additional injection.

Patients who are undergoing unilateral total knee replacement (TKR) and choose to participate will be randomly assigned to a treatment group.Patients in group one (treatment group) will receive a 30ml dose of .5% bupivacaine solution injected into the local anesthetic infiltration catheter immediately prior to its removal on postoperative day one. Patients in group two (control group) will receive no additional medication during local anesthetic infiltration catheter removal.

详细描述

The purpose of this study is to determine if an additional injection of local anesthetic immediately prior to removal of the local anesthetic infiltration catheter on postoperative day one is effective in increasing pain reduction, patient satisfaction or outcome measures following total knee replacement (TKR). It is hypothesized that an additional injection of 30ml of .5% bupivacaine solution immediately before infiltration catheter removal will provide pain reduction, patient satisfaction and outcome measures equal or superior to catheter removal with no additional injection. The target enrollment for this study is 50 participants, 25 in each of groups one and two.

Patients who are undergoing unilateral total knee replacement (TKR) at Brigham and Women's Faulkner Hospital and meet all eligibility criteria will be informed about the study and asked if they would like to participate. Upon agreement, patient's consent will be obtained and they will be randomly assigned to a treatment group. Patients in group one (treatment group) will receive a 30ml dose of 0.5% bupivacaine solution injected into the local anesthetic infiltration catheter immediately prior to its removal on postoperative day one. Patients in group two (control group) will receive no additional medication during local anesthetic infiltration catheter removal.

Members of both groups will be asked to complete Visual Analog Scale (VAS) pain and satisfaction surveys and also to track daily narcotic pain medication consumption during the first week postoperatively. Measures of swelling in the operative knee will be collected for members of both groups at the first routine postoperative appointment approximately one week after surgery. Swelling will be measured using a Perometer which calculates the total volume of the extremity in cubic centimeters (Pero-System, Wuppertal, Germany). Proprioception will be measured using a SD Balancer (Biodex Medical Systems, Shirley, NY) which calculates the the overall stability index (OSI) and compares it to age standardized data. Quadriceps strength using a handheld dynamometer. Outcome measures will be collected for members of both groups prior to surgery and at the second routine postoperative appointment between 6 weeks after surgery. Swelling will be also measured at the first post-operative visit 1 week after surgery. These data measures, as well as any complications will be recorded and used for analysis at the completion of the study.

The Principal Investigator (PI) will review all pain, satisfaction, narcotic usage and proprioception data on a weekly basis with the research assistant (RA) as it is collected. These checks will help to ensure validity and patient safety. Privacy and confidentially will be assured by using codes as deidentifiers in place of identifying information on any data sheets used in analysis. Data which identifies the patient will be made available only to investigators and stored only in a private folder on department computers protected with a firewall. No data will be shared outside of Partners. Adverse events will be promptly reported to the PHRC as per PHRC rules.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years of age
  • Undergoing unilateral knee replacement
  • If female, not pregnant
  • Agree to participate in the follow-up appointment
  • Understand and sign the informed consent form

排除标准

  • Bilateral TKA planned
  • Use of narcotic medication before surgery
  • Any other surgery within the three months prior to TKR
  • Inflammatory arthritis
  • Any chronic pain conditions or problems, including but not limited to chronic back pain, fibromyalgia or multiple sclerosis
  • Osteoarthritis of the non-operative knee
  • Osteoarthritis of one or both hips

研究组 & 干预措施

Injection

Experimental

Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal

干预措施: Bupivacaine (Drug)

No Injection

Active Comparator

Will not receive injection of bupivacaine prior to catheter removal

干预措施: No Intervention (Other)

结局指标

主要结局

Pain Assessed Using the VAS 0-10 Pain Scale

时间窗: 7 days

Pain will be assessed using the VAS 0-10 pain scale. 0 is no pain and 10 in worst imaginable pain.

次要结局

  • Swelling Measured Using a Perometer(7 days)
  • Quadriceps Strength Measured Using a Biodex Handheld Dynamometer"(7 days)
  • Pain Med Consumption Assessed Using Questionnaire/Hospital Records(7 days)
  • Proprioception Measured Using a SD Balancer(7 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wolfgang Fitz

Associate Orthopedic Surgeon

Brigham and Women's Hospital

相似试验